These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31816821)

  • 1. Changing Incidence and Stage Distribution of Prostate Cancer in a Lithuanian Population-Evidence from National PSA-Based Screening Program.
    Patasius A; Smailyte G
    Int J Environ Res Public Health; 2019 Dec; 16(23):. PubMed ID: 31816821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
    Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
    Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme.
    Smailyte G; Aleknaviciene B
    Public Health; 2012 Dec; 126(12):1075-7. PubMed ID: 22381571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
    Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
    Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
    Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
    Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia.
    Luo Q; Yu XQ; Kahn C; Egger S; Patel MI; Grogan PB; Caruana M; Canfell K; Smith DP; O'Connell DL
    Cancer Epidemiol; 2022 Jun; 78():102159. PubMed ID: 35447540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
    Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
    Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
    Stephenson RA; Smart CR; Mineau GP; James BC; Janerich DT; Dibble RL
    Cancer; 1996 Apr; 77(7):1342-8. PubMed ID: 8608513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in stage-specific incidence of prostate cancer in Norway, 1980-2010: a population-based study.
    Møller MH; Kristiansen IS; Beisland C; Rørvik J; Støvring H
    BJU Int; 2016 Oct; 118(4):547-55. PubMed ID: 26497872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
    Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
    Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
    Jonsson H; Holmström B; Duffy SW; Stattin P
    Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Trends in Prostate Cancer Incidence by Stage at Diagnosis in Japan Using the Multiple Imputation Approach, 1993-2014.
    Saito E; Hori M; Matsuda T; Yoneoka D; Ito Y; Katanoda K
    Cancer Epidemiol Biomarkers Prev; 2020 Jun; 29(6):1222-1228. PubMed ID: 32169995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
    Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
    Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of prostate cancer "reverse stage migration" toward more advanced disease at diagnosis: Data from the Pennsylvania Cancer Registry.
    Reese AC; Wessel SR; Fisher SG; Mydlo JH
    Urol Oncol; 2016 Aug; 34(8):335.e21-8. PubMed ID: 27108226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen.
    Stephenson RA; Stanford JL
    World J Urol; 1997; 15(6):331-5. PubMed ID: 9436281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent trends in prostate cancer in Canada.
    LeBlanc AG; Demers A; Shaw A
    Health Rep; 2019 Apr; 30(4):12-17. PubMed ID: 30994922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012.
    Hoffman RM; Meisner AL; Arap W; Barry M; Shah SK; Zeliadt SB; Wiggins CL
    Cancer Epidemiol Biomarkers Prev; 2016 Feb; 25(2):259-63. PubMed ID: 26646364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost implications of prostate cancer screening in the Medicare population.
    Ma X; Wang R; Long JB; Ross JS; Soulos PR; Yu JB; Makarov DV; Gold HT; Gross CP
    Cancer; 2014 Jan; 120(1):96-102. PubMed ID: 24122801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.